p27 expression as a prognostic factor of breast cancer in Taiwan

Cancer Letters

Volumn 141, Issue 1-2, 1999, Pages 123-130

  Chu, Jan Show ^a   Huang, Chiun Sheng ^b   Chang, King Jen ^b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Breast cancer; Immunohistochemistry; p27; Proliferating cell neuclear antigen

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P27;

ADULT; ARTICLE; BREAST CANCER; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR DENSITY; STATISTICAL ANALYSIS; SURVIVAL RATE; TAIWAN;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE; TAIWAN; TUMOR SUPPRESSOR PROTEINS;

EID: 0033012770     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00084-1     Document Type: Article

References (27)

1. Yang P.S., Yang T.L., Liu C.L., Wu C.W., Shen C.Y. A case control study of breast cancer in Taiwan - a low incidence area. Br. J. Cancer. 75:1997;752-756.
2. MacLachlan T.K., Sang N., Giordano A. Cyclin, cyclin-dependent kinases and Cdk inhibitors implication in cell cycle control and cancer. Crit. Rev. Eukaryotic Gene Exp. 5:1995;127-156.
3. Arellano M., Moreno S. Regulation of CDK/cyclin complexes during the cell cycle. Int. J. Biochem. 29:1997;559-573.
4. Koff A., Cross F., Fisher A., Schumacher J., Leguellec K., Philippe M., Roberts J.M. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell. 66:1991;1217-1228.
5. Polyak K., Lee M.H., Erdjement-Bromage H., Koff A., Toberts J.M., Tempst P., Massague J. Cloning of p27/kip1, a cyclin-dependent kinase inhibitor and a potent mediator of extracellular antimitogenic signals. Cell. 79:1994;59-66.
6. kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 372:1994;570-573.
7. Pagano M., Tam S.W., Theodoras A.M., Romero-Beer P., Del Sal G., Chau V., Yew R., Draetta G., Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 269:1995;682-685.
8. Alessandrini A., Chiaur D.S., Pagano M. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia. 13:1997;342-345.
9. Kawamata N., Morosetti R., Miller C.W., Park D., Spirin K.S., Nakamaki T., Takeuchi S., Hatta Y., Simpson J., Wilczynski S., Lee Y.Y., Bartram C.R., Koeffler H.P. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res. 55:1995;2266-2269.
10. Spirin K.S., Simpson J.F., Takeuchi S., Kawamata N., Miller C.W., Koeffler H.P. P27/Kip1 mutation found in breast cancer. Cancer Res. 56:1996;2400-2404.
11. Ferrando A.A., Balbin M., Pendas A.M., Vizoso F., Velasco G., Lopez-Otin C.F. Mutational analysis of the human-cyclin dependent kinase inhibitor p27kip1 in primary breast carcinomas. Hum. Genet. 97:1996;91-94.
12. Coats S., Flanagan W.M., Nourse J., Roberts J.M. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science. 272:1996;877-880.
13. 1a,b) invasive breast cancer. Cancer Res. 57:1997;1259-1263.
14. kip1 protein: prognostic implications in primary breast cancer. Nat. Med. 2:1997;227-230.
15. Porter P.L., Malone K.E., Heagerty P.J., Alexander G.M., Gatti L.A., Firpo E.J., Daling J.R., Roberts J.M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3:1997;222-225.
16. Fredersdorf S., Burns J., Milne A.M., Packham G., Fallis L., Gillett C.E., Royds J.A., Peston D., Hall P.A., Handy A.M., Barnes D.M., Shousha S., O'Hare M.J., Lu X. High level expression of p27 (kip1) and cyclin D1 in some human breast cancer: inverse correlation between the expression of p27 (kip1) and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. USA. 94:1997;6380-6385.
17. Loda M., Cukor B., Tam S.W., Lavin P., Fiorentino M., Draetta G.F., Jessup J.M., Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinoma. Nat. Med. 2:1997;231-234.
18. Yasui W., Kudo Y., Semba S., Yokozaki H., Tahara E. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn. J. Cancer Res. 88:1997;625-629.
19. Yang R.M., Naitoh J., Murphy M., Wang H.J., Phillipson J., deKernion J.B., Loda M., Reiter R.E. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol. 159:1998;941-945.
20. Esposito V., Baldi A., De Luca A., Groger A.M., Loda M., Giordano G.G., Caputi M., Baldi F., Pagano M., Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 57:1997;3381-3385.
21. Thomas G.V., Szigeti K., Murphy M., Draetta G., Pagano M., Loda M. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am. J. Pathol. 153:1998;681-687.
22. Anayama T., Furihata M., Ishikawa T., Ohtsuki Y., Ogoshi S. Positive correlation between p27Kip1 expression and progression of human esophageal squamous cell carcinoma. Int. J. Cancer. 79:1998;439-443.
23. Cheville J.C., Lloyd R.V., Sebo T.J., Cheng L., Erickson L., Bostwick D.G., Lohse C.M., Wollan P. Expression of p27kip1 in prostatic adenocarcinoma. Mod. Pathol. 11:1998;324-328.
24. Singh S.P., Lipman J., Goldman H., Ellis F.H. Jr., Aizenman L., Cangi M.G., Signoretti S., Chiaur D.S., Pagano M., Loda M. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 58:1998;1730-1735.
25. Elaston C.W., Ellis I.O. Pathologic factors in breast cancer: the value of histologic grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 19:1991;404-410.
26. Chu J.S., Huang C.S., Chang K.J. Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in invasive ductal carcinoma of breast in Taiwan. Cancer Lett. 131:1998;145-152.
27. Kip1 accumulation during the cell cycle. Science. 271:1996;1861-1864.